Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Varun Saxena,Vandana Khungar,Elizabeth C. Verna,Josh Levitsky,Robert S. Brown,Mohamed Hassan,Mark S. Sulkowski,Jacqueline G. O'Leary,Farrukh M. Koraishy,Joseph S. Galati,Alexander Kuo,Monika Vainorius,Lucy Akushevich,David R. Nelson,Michael W. Fried,Norah A. Terrault,K. Rajender Reddy +16 more
TLDR
In a large prospective observational cohort study, direct‐acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvir, and SOF plus daclatasvir was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was rare.About:
This article is published in Hepatology.The article was published on 2017-10-01 and is currently open access. It has received 146 citations till now. The article focuses on the topics: Ombitasvir & Paritaprevir.read more
Citations
More filters
Journal ArticleDOI
EASL Recommendations on Treatment of Hepatitis C
Jean-Michel Pawlotsky,Alessio Aghemo,Geoffrey Dusheiko,Xavier Forns,Massimo Puoti,Christophe Sarrazin +5 more
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation.
Journal ArticleDOI
EASL recommendations on treatment of hepatitis C: Final update of the series ☆
Jean-Michel Pawlotsky,Francesco Negro,Alessio Aghemo,Marina Berenguer,Olav Dalgard,Geoffrey Dusheiko,Fiona Marra,Massimo Puoti,Heiner Wedemeyer +8 more
TL;DR: These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.
Journal ArticleDOI
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Marc G. Ghany,Timothy R. Morgan +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C virus guidance project (hereafter HCV guidance) in 2013 and disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of HCV infection.
Journal ArticleDOI
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial
Christine M. Durand,Mary G. Bowring,Diane M. Brown,Michael A. Chattergoon,Guido Massaccesi,Nichole Bair,Russell Wesson,Ashraf Reyad,Fizza F. Naqvi,Darin Ostrander,Jeremy Sugarman,Dorry L. Segev,Mark S. Sulkowski,Niraj M. Desai +13 more
TL;DR: In this article, a kidney from HCV-infected (HCV+) donors may be a neglected public health resource, given the high mortality rate for those with end-stage kidney d sease on dialysis.
References
More filters
Journal ArticleDOI
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris,Robert W. Taylor,Robert J. Thielke,Jonathon Payne,Nathaniel Gonzalez,José G. Conde +5 more
TL;DR: Research electronic data capture (REDCap) is a novel workflow methodology and software solution designed for rapid development and deployment of electronic data Capture tools to support clinical and translational research.
Journal ArticleDOI
Bias reduction of maximum likelihood estimates
TL;DR: In this paper, the first-order term is removed from the asymptotic bias of maximum likelihood estimates by a suitable modification of the score function, and the effect is to penalize the likelihood by the Jeffreys invariant prior.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produced high rates of SVR12 in patients with advanced liver disease, including those with decompensated cirrhosis before and after liver transplantation.
Journal ArticleDOI
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
TL;DR: In this article, the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuvir, and ribavirin were used to treat chronic hepatitis C virus (HCV) infection in patients with advanced liver disease.
Journal ArticleDOI
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns,Didier Samuel,Edward Gane,David Mutimer,Geoff McCaughan,Maria Buti,Martín Prieto,Jose Luis Calleja,Markus Peck-Radosavljevic,Beat Müllhaupt,Kosh Agarwal,Peter W Angus,Eric M. Yoshida,Massimo Colombo,Mario Rizzetto,Hadas Dvory-Sobol,Jill Denning,Sarah Arterburn,Phillip S. Pang,Diana M. Brainard,John G. McHutchison,Jean-François Dufour,Hans Van Vlierberghe,Bart van Hoek,Xavier Forns +24 more
TL;DR: An open-label study assessing the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advanced liver disease found high rates of sustained virological response 12 weeks after treatment.
Related Papers (5)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton,Gregory T. Everson,Steven L. Flamm,Princy Kumar,Charles Landis,Robert S. Brown,Michael W. Fried,Norah A. Terrault,Jacqueline G. O'Leary,Hugo E. Vargas,Alexander Kuo,Eugene R. Schiff,Mark S. Sulkowski,Richard Gilroy,Kymberly D. Watt,Kimberly A Brown,Paul Y. Kwo,Surakit Pungpapong,Kevin M. Korenblat,Andrew J. Muir,Lewis Teperman,Robert J. Fontana,Jill Denning,Sarah Arterburn,Hadas Dvory-Sobol,Theo S. Brandt-Sarif,Phillip S. Pang,John G. McHutchison,K. Rajender Reddy,Nezam H. Afdhal +29 more
The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation
Josh Levitsky,Richard N. Formica,Roy D. Bloom,Michael Charlton,Michael P. Curry,John J. Friedewald,Joelle Y. Friedman,David S. Goldberg,Shelley A. Hall,Michael G. Ison,Tiffany E. Kaiser,David K. Klassen,G Klintmalm,Jon A. Kobashigawa,AnnMarie Liapakis,K. O'Conner,Peter P. Reese,Darren Stewart,Norah A. Terrault,Nicole Theodoropoulos,James F. Trotter,Elizabeth C. Verna,Michael L. Volk +22 more
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
David Roth,David R. Nelson,Annette Bruchfeld,AnnMarie Liapakis,Marcelo Silva,Howard Paul Monsour,Paul J. Martin,Stanislas Pol,Maria Carlota Londoño,Tarek Hassanein,Philippe J. Zamor,Eli Zuckerman,Shuyan Wan,Beth Jackson,Bach-Yen Nguyen,Michael N. Robertson,Eliav Barr,Janice Wahl,Wayne Greaves +18 more
Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients
David S. Goldberg,Peter L. Abt,Emily A. Blumberg,Vivianna M. Van Deerlin,Matthew H. Levine,K. Rajender Reddy,Roy D. Bloom,Susanna M. Nazarian,Deirdre Sawinski,Paige M. Porrett,Ali Naji,Richard Hasz,Lawrence Suplee,Jennifer Trofe-Clark,Anna Sicilia,Maureen McCauley,Midhat S. Farooqi,Caren Gentile,Jennifer R. Smith,Peter P. Reese +19 more
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns,Didier Samuel,Edward Gane,David Mutimer,Geoff McCaughan,Maria Buti,Martín Prieto,Jose Luis Calleja,Markus Peck-Radosavljevic,Beat Müllhaupt,Kosh Agarwal,Peter W Angus,Eric M. Yoshida,Massimo Colombo,Mario Rizzetto,Hadas Dvory-Sobol,Jill Denning,Sarah Arterburn,Phillip S. Pang,Diana M. Brainard,John G. McHutchison,Jean-François Dufour,Hans Van Vlierberghe,Bart van Hoek,Xavier Forns +24 more